[HTML][HTML] LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer …
Background PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC.
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …
IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
JS de Bono, S Bracarda, CN Sternberg, KN Chi… - Annals of …, 2020 - elibrary.ru
PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC. PTEN loss
(40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse outcomes …
(40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse outcomes …
[PDF][PDF] GENITOURINARY TUMOURS, PROSTATE
JS de Bono, S Bracarda, CN Sternberg, KN Chi… - researchgate.net
Background: PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC.
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …